BioCaptiva develops msX™, a proprietary polymer technology that captures circulating free DNA (cfDNA) directly from biological fluids without additional reagents, enhancing sample yield and stability. This technology addresses the limitations of current liquid biopsy methods, enabling non-invasive cancer diagnosis and monitoring with improved sample quality and reduced risk of failure.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AFounders
Product
Problem
Current liquid biopsy methods for cancer diagnosis and monitoring are limited by restricted sample volumes, poor sample quality, and the need for additional reagents, leading to potential sample failure and hindering the development of personalized treatment plans. Existing techniques often struggle to capture sufficient circulating free DNA (cfDNA) from biological fluids, impacting the accuracy and reliability of downstream analyses.
Solution
BioCaptiva's msX™ technology directly captures cfDNA from biological fluids without the need for additional reagents, addressing the limitations of current liquid biopsy methods. The proprietary polymer enhances cfDNA yield and provides exceptional sample stability, minimizing pre-analytical processing. msX™ selectively targets cfDNA, improving signal-to-noise ratios by minimizing high molecular weight and cellular DNA contamination. The technology is adaptable to various biofluids, including plasma, whole blood, urine, and pleural effusion, and can be coated onto diverse substrates such as beads, foams, or solid surfaces. cfDNA bound by msX™ can be stored stably for up to 90 days at room temperature before concentration into a PCR- and NGS-compatible format.
Target Audience
The primary target audience includes researchers, clinicians, and diagnostic companies involved in liquid biopsy, non-invasive cancer diagnosis, disease monitoring, and personalized medicine.
Features
- Direct cfDNA capture from biological fluids without additional reagents
- Enhanced cfDNA yield and exceptional sample stability for up to 90 days at room temperature
- Selective binding of low molecular weight DNA to improve signal-to-noise ratios
- Adaptable to various biofluids (plasma, whole blood, urine, pleural effusion)
- Can be coated onto diverse substrates (beads, foams, solid surfaces)
- Suitable for large volume flow-through solutions
- Produced under an ISO 13485 compliant quality management system